Fig. 1.

SHP2 knockdown differentially impacts GBM cell proliferation and survival. (A) U87MG, LN18, T98G and U118MG cells that express control or SHP2-targeting shRNA were seeded at 100,000 cells/well, and cells were counted 72 h later. Counts are represented as the mean ± s.e.m. (n = 3); *P<0.05. (B) The indicated cell lines were co-treated with 20 µM gefitinib + 1 µM PHA665752 (G+P) or with DMSO as a control (DMSO). After 72 h, the percentage of TO-PRO-3-positive cells was measured by flow cytometry (n = 3); *P<0.05. (C) The indicated cell lines expressing control or SHP2-targeting shRNA were maintained in complete medium. Lysates were analyzed by western blotting using antibodies against the indicated proteins. Densitometry data are represented as the mean ± s.e.m. (n = 3); *P<0.05.